W78. Resistance Testing Primer and Re-treatment Options for HCV Patients
Session: Premeeting Workshop: Hepatitis C Workshop
Wednesday, October 3, 2018: 9:10 AM
Room: S 156
David L. Wyles, MD, Medicine, Denver Health Medical Center/University of Colorado, Denver, CO

Dr. David Wyles is a Professor of Medicine in the Division of Infectious Diseases at the University of Colorado and Chief of the Division of Infectious Diseases at Denver Health Medical Center. Dr. Wyles’ research interests include the conduct of HCV clinical trials, HCV drug resistance and the treatment of HCV in underserved populations. He was an inaugural member of the AASLD/IDSA HCV guidelines panel. He currently serves on the International Antiviral Society – USA Hepatitis Advisory Board and the ACTG Hepatitis transformative science group. Clinically Dr. Wyles is involved in care of patients with HCV and HCV/HIV-1 co-infection.


Disclosures:

D. L. Wyles, 1970: Consultant , Grant Investigator , Research Contractor and Scientific Advisor , Consulting fee , Research grant and Research support .

See more of: Hepatitis C Workshop
See more of: Premeeting Workshop

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.